Pharmabiz13h
EMA committee recommends approval of AbbVie’s upadacitinib to treat adults with giant cell arteritis
EMA committee recommends approval of AbbVie’s upadacitinib to treat adults with giant cell arteritis: North Chicago, Illinois Monday, March 3, 2025, 15:00 Hrs [IST] AbbVie annou ...
Hosted on MSN2d
CHMP recommends AbbVie’s Rinvoq be approved for adult GCA
The treatment has gained approval in the European Union (EU) for a range of conditions, including psoriatic arthritis, ...
AbbVie's Next Big Moneymaker? This Drug Just Took a Huge Step Toward Approval
A key regulatory win could turn this under-the-radar treatment into AbbVie's next billion-dollar success story.
AbbVie gets EU nod for its giant cell arteritis treatment
AbbVie (NYSE:ABBV) announced Friday that an expert panel of the EU drug regulator, the European Medicines Agency (EMA), ...
AbbVie announces CHMP opinion recommending approval of upadacitinib
AbbVie (ABBV) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted an opinion recommending the ...
Nasdaq3d
AbbVie's Upadacitinib Gets Positive CHMP Opinion For Treatment Of Adults With Giant Cell Arteritis
(RTTNews) - AbbVie (ABBV) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of upadacitinib ...
MedPage Today11d
Upadacitinib Plus Topical Steroids: Impact on Moderate-to-Severe Atopic Dermatitis?
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Upadacitinib combined with topical corticosteroids led to rapid and lasting relief from atopic dermatitis (AD ...
pharmaphorum7d
AbbVie’s JAK inhibitor upadacitinib gets Priority Review
AbbVie said it anticipates a regulatory decision on upadacitinib from the FDA in Q3 2019. The drug is also under review by the European Medicines Agency for the treatment of adult patients with ...
pharmaphorum8d
AbbVie prices Rinvoq close to Humira after arthritis approval
AbbVie claimed FDA approval for its JAK inhibitor Rinvoq (upadacitinib) for rheumatoid arthritis on Friday, setting its price just a little below that of its antibody blockbuster Humira.
Morningstar3d
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Giant Cell Arteritis
The final European Commission decision is expected in the first half of 2025. If approved, upadacitinib would be the first and only oral advanced therapy for adults living with GCA. "Giant cell ...
Yahoo Finance3d
CHMP recommends AbbVie’s Rinvoq be approved for adult GCA
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of AbbVie's upadacitinib (Rinvoq) to treat adults with giant cell arteritis (GCA).
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Giant Cell Arteritis
AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of upadacitinib ...